ATE322905T1 - Verfahren zur hemmung der fibrose mittels eines somatostatin-agonisten - Google Patents

Verfahren zur hemmung der fibrose mittels eines somatostatin-agonisten

Info

Publication number: ATE322905T1
Authority: AT; Austria
Prior art keywords: inhibiting fibrosis; somatostatin agonist; somatostatin; patient; agonist
Prior art date: 1996-08-30

Application number

AT97939392T

Other languages

English (en)

Inventor

Michael D Culler

Philip G Kasprzyk

Original Assignee

Sod Conseils Rech Applic

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-30

Filing date

1997-08-27

Publication date

2006-04-15

1997-08-27 Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic

2006-04-15 Application granted granted Critical

2006-04-15 Publication of ATE322905T1 publication Critical patent/ATE322905T1/de

Links

102000005157 Somatostatin Human genes 0.000 title abstract 3
108010056088 Somatostatin Proteins 0.000 title abstract 3
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title abstract 3
229960000553 somatostatin Drugs 0.000 title abstract 3
206010016654 Fibrosis Diseases 0.000 title abstract 2
239000000556 agonist Substances 0.000 title abstract 2
230000004761 fibrosis Effects 0.000 title abstract 2
230000002401 inhibitory effect Effects 0.000 title abstract 2
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)
Zoology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Ophthalmology & Optometry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Transplantation (AREA)
Neurology (AREA)
AIDS & HIV (AREA)

AT97939392T 1996-08-30 1997-08-27 Verfahren zur hemmung der fibrose mittels eines somatostatin-agonisten ATE322905T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US70579096A	1996-08-30	1996-08-30

Publications (1)

Publication Number	Publication Date
ATE322905T1 true ATE322905T1 (de)	2006-04-15

Family

ID=24834961

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97939392T ATE322905T1 (de)	1996-08-30	1997-08-27	Verfahren zur hemmung der fibrose mittels eines somatostatin-agonisten

Country Status (13)

Country	Link
US (3)	US6268342B1 (de)
EP (2)	EP1574219A3 (de)
JP (2)	JP2001500483A (de)
CN (1)	CN1229357A (de)
AT (1)	ATE322905T1 (de)
AU (2)	AU3215597A (de)
CA (1)	CA2264309A1 (de)
DE (1)	DE69735674T2 (de)
ES (1)	ES2258282T3 (de)
HU (1)	HUP9903918A3 (de)
PL (1)	PL331922A1 (de)
WO (2)	WO1998008528A1 (de)
ZA (1)	ZA977783B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998008528A1 (en) *	1996-08-30	1998-03-05	Biomeasure Incorporated	Method of inhibiting fibrosis with a somatostatin agonist
US5968903A (en) *	1998-05-07	1999-10-19	Biomeasure, Incorporated	Inhibition of H. pylori proliferation
IL140837A0 (en) *	1998-07-30	2002-02-10	Sod Conseils Rech Applic	Method of using lanreotide, a somatostatin analogue
US6150333A (en) *	1998-07-30	2000-11-21	Biomeasure, Inc.	Methods of using a somatostatin analogue
EP1291022A1 (de) *	1998-07-30	2003-03-12	Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.	Anwendungsverfahren für lanreotid, ein somatostatin analogon
IES990700A2 (en) *	1999-08-18	2001-08-22	Kinerton Ltd	Process to make a sustained release formulation
PT1263464E (pt)	2000-03-09	2012-12-17	Genzyme Corp	Utilização de anticorpos anti-tgf-beta antagonistas para tratar ou para prevenir a perda da função renal
DK1372688T3 (da)	2001-03-08	2008-08-25	Univ Tulane	Somatostatin-antagonister
CN1541102A (zh) *	2001-04-09	2004-10-27		生长激素抑制素激动剂
WO2003016476A2 (en) *	2001-08-14	2003-02-27	Gene Logic, Inc.	Gene expression profiles in glomerular diseases
US20070098784A1 (en)	2001-09-28	2007-05-03	Nutraceutix, Inc.	Delivery system for biological component
WO2003057214A1 (en) *	2001-12-28	2003-07-17	Somatocor Pharmaceuticals, Inc.	Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands
JP4603976B2 (ja) *	2002-10-31	2010-12-22	千寿製薬株式会社	角膜障害治療剤
US20050043272A1 (en) *	2003-07-11	2005-02-24	Pro-Pharmaceuticals, Inc.	Compositions and methods for hydrophobic drug delivery
US20050053664A1 (en) *	2003-09-08	2005-03-10	Eliezer Zomer	Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
EP1522311A1 (de) *	2003-10-10	2005-04-13	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Verwendung von Somatostatin oder seine Derivate zur Herstellung eines Medikamentes zur Regulierung der Ovarialfollikelnreserve bei der nicht menopausierte Frau
US20070078109A1 (en) *	2004-02-13	2007-04-05	David Platt	Compositions and methods used to treat acne and candida
WO2005082844A1 (en) *	2004-02-27	2005-09-09	Oy Juvantia Pharma Ltd	Treatment of diseases by using a somatostatin receptor agonist
WO2005082845A1 (en) *	2004-02-27	2005-09-09	Oy Juvantia Pharma Ltd	Novel therapies with somatostatin receptor agonists
WO2005089316A2 (en)	2004-03-12	2005-09-29	Intercept Pharmaceuticals, Inc.	Treatment of fibrosis using fxr ligands
CN1961003B (zh)	2004-03-31	2013-03-27	健泰科生物技术公司	人源化抗TGF-β抗体
WO2006017417A2 (en) *	2004-08-02	2006-02-16	Pro-Pharmaceuticals, Inc.	Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
EP2862867A3 (de)	2005-10-25	2015-08-05	The Johns Hopkins University	Verfahren und Zusammensetzungen zur Behandlung des Marfan-Syndroms und assoziierter Erkrankungen
EP2230252A1 (de)	2006-03-13	2010-09-22	The Johns Hopkins University	Erhöhung der endothelialen Thromboresistenz
WO2008011216A2 (en)	2006-05-16	2008-01-24	Pro-Pharmaceuticals, Inc.	Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
FR2907682B1 (fr) *	2006-10-26	2012-12-07	Vincience	Composition cosmetique et/ou pharmaceutique comprenant comme principe actif au moins un peptide et utilisation de ce peptide.
AU2008306264A1 (en) *	2007-09-11	2009-04-09	Mondobiotech Laboratories Ag	Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents
BRPI0915142A8 (pt)	2008-06-12	2018-01-02	Syntaxin Ltd	Polipeptídeos, ácido nucleico e usos dos mesmos
JP5728380B2 (ja)	2008-06-12	2015-06-03	シンタクシンリミテッドＳｙｎｔａｘｉｎＬｉｍｉｔｅｄ	神経内分泌疾患の抑制
GB0820970D0 (en)	2008-11-17	2008-12-24	Syntaxin Ltd	Suppression of cancer
EP3117709B1 (de)	2010-03-12	2018-08-01	Genzyme Corporation	Kombinationstherapie zur behandlung von brustkrebs
WO2011151782A1 (en)	2010-06-02	2011-12-08	Preglem Sa	A role for somatostatin to modulate initiation of follicular growth in the human ovary
EP2399931A1 (de) *	2010-06-22	2011-12-28	Ipsen Pharma S.A.S.	Neue Oktapeptid-Verbindungen und ihr therapeutischer Einsatz
US8956868B2 (en)	2010-12-27	2015-02-17	Lsip, Llc	Induced pluripotent stem cells produced with a connexin inhibitor and a TGF-β signaling inhibitor
US20150044178A1 (en)	2011-12-28	2015-02-12	Kyoto Prefectural Public University Corporation	Normalization of culture of corneal endothelial cells
JP2016503402A (ja)	2012-11-01	2016-02-04	イプセンファルマソシエテパールアクシオンサンプリフィエＩｐｓｅｎＰｈａｒｍａＳ．Ａ．Ｓ．	ソマトスタチン類似体及びそのダイマー
TWI523863B (zh) *	2012-11-01	2016-03-01	艾普森藥品公司	體抑素－多巴胺嵌合體類似物
EP3266782B1 (de)	2013-02-07	2019-10-30	SciFluor Life Sciences, Inc.	Fluorierte integrin-antagonisten
US9339515B2 (en)	2013-02-20	2016-05-17	Galectin Therapeutics, Inc.	Method for treatment of pulmonary fibrosis
CA2927898C (en)	2013-10-31	2021-11-16	Kyoto Prefectural Public University Corporation	Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
EP3925959A1 (de)	2015-02-19	2021-12-22	OcuTerra Therapeutics, Inc.	Fluorierte derivate von 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propansäure und verwendungen davon
JP2018514568A (ja)	2015-04-30	2018-06-07	サイフルーアライフサイエンシズインコーポレイテッド	テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法
WO2016187312A1 (en)	2015-05-18	2016-11-24	The Arizona Board Of Regents On Behalf Of The University Of Arizona	Methods and compositions for treating an alphavirus infection
US10118929B2 (en)	2016-04-27	2018-11-06	Scifluor Life Sciences, Inc.	Nonanoic and decanoic acid derivatives and uses thereof
GB201816637D0 (en) *	2018-10-12	2018-11-28	Heptares Therapeutics Ltd	Selective somatostatin receptor agonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GR862206B (en) *	1985-09-12	1986-12-31	Univ Tulane	Therapeutic somatostatin analogs
US4904642A (en) *	1985-09-12	1990-02-27	The Administrators Of The Tulane Educational Fund	Therapeutic somatostatin analogs
US4853371A (en)	1986-06-17	1989-08-01	The Administrators Of The Tulane Educational Fund	Therapeutic somatostatin analogs
GB8716324D0 (en)	1987-07-10	1987-08-19	Sandoz Ltd	Organic compounds
DE3822557C2 (de)	1987-07-10	1998-07-02	Ciba Geigy Ag	Arzneimittel, enthaltend Somatostatine
CA2053250A1 (en)	1989-04-26	1990-10-27	David H. Coy	Linear somatostatin analogs
HU207104B (en)	1991-01-25	1993-03-01	Biosignal Kutato Fejlesztoe Kf	Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds
WO1997032604A1 (en) *	1996-03-07	1997-09-12	Novartis Ag	Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
WO1998008528A1 (en) *	1996-08-30	1998-03-05	Biomeasure Incorporated	Method of inhibiting fibrosis with a somatostatin agonist

1997
- 1997-05-28 WO PCT/US1997/008999 patent/WO1998008528A1/en not_active Ceased
- 1997-05-28 AU AU32155/97A patent/AU3215597A/en not_active Abandoned
- 1997-08-27 WO PCT/US1997/014154 patent/WO1998008529A1/en not_active Ceased
- 1997-08-27 CA CA002264309A patent/CA2264309A1/en not_active Abandoned
- 1997-08-27 EP EP05076124A patent/EP1574219A3/de not_active Withdrawn
- 1997-08-27 JP JP10511678A patent/JP2001500483A/ja active Pending
- 1997-08-27 CN CN97197671A patent/CN1229357A/zh active Pending
- 1997-08-27 HU HU9903918A patent/HUP9903918A3/hu unknown
- 1997-08-27 PL PL97331922A patent/PL331922A1/xx unknown
- 1997-08-27 AU AU41490/97A patent/AU726731B2/en not_active Ceased
- 1997-08-27 AT AT97939392T patent/ATE322905T1/de not_active IP Right Cessation
- 1997-08-27 ES ES97939392T patent/ES2258282T3/es not_active Expired - Lifetime
- 1997-08-27 US US09/254,097 patent/US6268342B1/en not_active Expired - Fee Related
- 1997-08-27 DE DE69735674T patent/DE69735674T2/de not_active Expired - Lifetime
- 1997-08-27 EP EP97939392A patent/EP0938328B1/de not_active Expired - Lifetime
- 1997-08-29 ZA ZA977783A patent/ZA977783B/xx unknown
2001
- 2001-01-16 US US09/761,605 patent/US6787521B2/en not_active Expired - Fee Related
2004
- 2004-09-07 US US10/935,593 patent/US7238666B2/en not_active Expired - Fee Related
2007
- 2007-10-11 JP JP2007265712A patent/JP2008074857A/ja active Pending

Also Published As

Publication number	Publication date
WO1998008529A1 (en)	1998-03-05
AU4149097A (en)	1998-03-19
EP0938328B1 (de)	2006-04-12
US20010011072A1 (en)	2001-08-02
CN1229357A (zh)	1999-09-22
JP2008074857A (ja)	2008-04-03
PL331922A1 (en)	1999-08-16
AU3215597A (en)	1998-03-19
HUP9903918A2 (hu)	2000-04-28
WO1998008528A1 (en)	1998-03-05
HUP9903918A3 (en)	2000-07-28
EP1574219A2 (de)	2005-09-14
JP2001500483A (ja)	2001-01-16
CA2264309A1 (en)	1998-03-05
EP0938328A1 (de)	1999-09-01
EP1574219A3 (de)	2006-04-26
US6787521B2 (en)	2004-09-07
DE69735674D1 (de)	2006-05-24
DE69735674T2 (de)	2007-04-05
US7238666B2 (en)	2007-07-03
AU726731B2 (en)	2000-11-16
US20050222025A1 (en)	2005-10-06
EP0938328A4 (de)	2002-08-28
US6268342B1 (en)	2001-07-31
ZA977783B (en)	1999-03-01
ES2258282T3 (es)	2006-08-16

Legal Events

Date	Code	Title	Description
2006-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69735674D1 (de)	2006-05-24	Verfahren zur hemmung der fibrose mittels eines somatostatin-agonisten
UA27224C2 (uk)	2000-08-15	Арилалкіламіни, спосіб їх одержання та фармацевтична композиція
NO20003050D0 (no)	2000-06-14	Metode for Õ administrere monomere insulinanaloger
DE69738185D1 (de)	2007-11-15	Verfahren zur Herstellung eines bluddrucksenkenden Mittel enthaltenden ein Dipeptid als wirksames Bestandteil
DE68905312D1 (de)	1993-04-15	Verfahren zur verbesserung der haertung eines lichthaertenden zahnrestaurationsmaterials.
EP0981360A4 (de)	2001-05-23	Verfahren zur prevention von gastritis unter verwedund von amylin oder amylin agonisten
SE9803760D0 (sv)	1998-11-04	Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
ATA903796A (de)	2005-08-15	Elektrotransporteinrichtung zur verabreichung eines als fentanylsalz oder als sufentanilsalz vorliegenden analgetischen medikaments
DE69837322D1 (de)	2007-04-26	Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
PL350568A1 (en)	2002-12-16	N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
DE60019320D1 (de)	2005-05-12	Verbessertes verfahren zur ermittlung der schleifenkonfiguration eines teilnehmers
HU9700661D0 (en)	1997-05-28	Use of alpha-1-adrenoreceptor antagonists for profilacting and treating cancer
ATE212221T1 (de)	2002-02-15	Verfahren zum herstellen von extrakt enthaltenden pharmazeutischen formulierungen
DE69721812D1 (de)	2003-06-12	Verfahren zur herstellung optisch aktiver 3-quinuclidinol derivate
DE60004996D1 (de)	2003-10-09	Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen
IL126158A0 (en)	1999-05-09	Method for treating substance abuse
DE69800906D1 (de)	2001-07-19	Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
MY124089A (en)	2006-06-30	Use of cetirizine for preventing the onset of asthma
EP0900567A3 (de)	2001-05-02	Quinazolin-4-on AMPA Antagonisten zur Behandlung von motorischen Fehlfunktionen verbunden mit Dopaminagonist Therapie
IT1303675B1 (it)	2001-02-23	Metodo di determinazione di peptidi utilizzati come marker per ladiagnosi dell'autismo
DK1011672T3 (da)	2006-02-06	Anvendelse af (E)-metanicotin derivater til frembringelse af analgetiske virkninger
HUP0002727A2 (hu)	2001-08-28	Eljárás fibrinogén csökkentésére benzotiofénszármazékok felhasználásával
SE9501773D0 (sv)	1995-05-15	New use
EE200100122A (et)	2002-06-17	R-(+)-alfa-(2,3-dimetoksüfenüül)-1-[2-(4-fluorofenüül)etüül]-4-piperidiinmetanooli kasutamine unehäirete raviks
JO2127B1 (en)	2000-05-21	How to prevent asthma